WebHologic announced a $230 million deal in which it will acquire Biotheranostics, a private company that provides molecular diagnostic tests for breast and metastatic cancers. Through the purchase, Hologic aims to enhance its current work in the field of oncology with more personalized treatment and better outcomes for women. WebBreast Cancer Index™ (BCI) is the only test recognized by NCCN Clinical Practice Guidelines in Oncology (NCCN ® Guidelines) and the American Society of Clinical …
Hologic to acquire Biotheranostics for $230M - MassDevice
WebSign in or register to place Hologic product orders online (consumables only), download and view secure product documentation, search employment opportunities and set up job alerts or access training … WebAccess and use of the Biotheranostics Web site is subject to the terms and conditions set forth herein and all applicable laws, statutes, and/or regulations. Biotheranostics does not, by or through this Web site, offer for sale any products or services. Biotheranostics may revise or modify these terms and conditions from time to time. city clg science and commerce multan
Hologic To Buy Biotheranostics For $230M; Top Analyst
WebJan 6, 2024 · On Monday, it announced acquisition of Somatex Medical for $64 million, a buy also in the women's health space. Hologic's $230 million valuation is roughly seven … WebJan 5, 2024 · – Transaction Accelerates Hologic’s Entry into Oncology Growth Market, Provides New Lab Capabilities – – Hologic’s Commercial Resources, Expertise in … WebIn a clinical study of 547 patients considered to be clinically low risk (T1N0), Breast Cancer Index identified ~25% as likely to benefit from extended endocrine therapy and high risk of late distant recurrence. References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) for Breast ... dicted to style with gary della-bate